~~<i id='E8B7264B9E'><strike id='E8B7264B9E'><tt id='E8B7264B9E'><pre id='E8B7264B9E'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：hotspot 2025-10-02 11:36:00 Page View：2649

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As digital health tech proliferates, a new institute aims to cut through hype
Next article： Medical leaders decry Supreme Court decision on affirmative action

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

AdobeThehealthrecordscompanyNextGenHealthcarewillpay$31milliontoresolveallegationsthatitpaidkickback

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

Why hospitals are withdrawing from US News rankings

UniversityofPennsylvaniahospitalcomplexJonLovette/AlamyMercyPhiladelphiaHospitalwasplanningonshuttin